drugset / Trial / NCT03503292
Pharmacogenomics and Post-Operative Nausea and Vomiting
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Timeline
- Start
- 2018-05-02
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Granisetron | Other / unclassified | 1 mg | Intravenous |
| Subject | Ondansetron | Other / unclassified | 4 mg | Intravenous |
Indications
No indication recorded.